IDEAYA Biosciences Shares Surge 27% Following Positive OptimUM-02 Trial Results

IDEAYA Biosciences (NASDAQ: IDYA) saw its shares surge 27% on Monday after the company announced positive topline results from a pivotal clinical trial. The Phase 2/3 OptimUM-02 registrational trial evaluated the efficacy of darovasertib combined with crizotinib as a first-line treatment for metastatic uveal melanoma.

Efficacy Data and Trial Design

The OptimUM-02 trial successfully met its primary endpoint by demonstrating a statistically significant improvement in median progression-free survival (PFS). Specifically, patients receiving the darovasertib combination achieved a median PFS of 6.9 months. In contrast, patients receiving the investigator’s choice of therapy achieved a median PFS of only 3.1 months. This outcome yielded a hazard ratio of 0.42 (95% CI:0.30, 0.59), highlighting a robust clinical benefit.

IDEAYA enrolled 313 patients with HLA-A02:01-negative metastatic uveal melanoma in the study. The company assigned 210 patients to the darovasertib combination arm and 103 patients to the investigator’s choice arm. Within the control group, 76% of patients received a combination of ipilimumab and nivolumab, while the remaining 24% received pembrolizumab.

Secondary Endpoints and Safety Profile

Furthermore, the darovasertib combination delivered substantial improvements across secondary endpoints. The experimental treatment arm achieved an overall response rate of 37.1%, significantly outperforming the 5.8% response rate observed in the control group. Additionally, a blinded independent central review confirmed that the darovasertib combination reduced the risk of disease progression by 58%.

While overall survival data remains immature, IDEAYA noted an early trend indicating survival improvement for the darovasertib arm. Patients generally tolerated the treatment well, and the safety profile proved manageable. The medical team identified diarrhea, syncope, and hypotension as the most common Grade 3 or higher treatment-emergent adverse events.

Regulatory Outlook and Next Steps

Consequently, IDEAYA plans to submit a New Drug Application to the U.S. Food and Drug Administration during the second half of 2026. The company intends to leverage these trial results to support a request for accelerated approval.

Moreover, IDEAYA expects to present the complete data set from the OptimUM-02 trial at a major medical conference later in 2026. The company conducted this pivotal trial in collaboration with Servier, an international pharmaceutical group, underscoring a strategic partnership in advancing oncological treatments.

For more investor relations information on IDEAYA Biosciences please visit www.ir.ideayabio.com.